Mounjaro 7.5 mg Pen

Mounjaro 7.5 mg Pen

Description:

Mounjaro 7.5 mg Pen is a prescription injectable diabetes and weight management medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist. It is used once weekly as a subcutaneous injection to help improve blood sugar control in adults with type 2 diabetes and to support medically supervised weight loss and weight maintenance in eligible adults. Mounjaro is typically used as an adjunct to diet and exercise and may be used alone or in combination with other antidiabetic medications under medical supervision.

Indications:

• Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• • In combination with other medicinal products for the treatment of diabetes (e.g. insulin, metformin, SGLT2 inhibitors, etc.) as prescribed by a physician.
• Weight management in adults (weight loss and weight maintenance) as an adjunct to a reduced-calorie diet and increased physical activity in:
• • Adults with a body mass index (BMI) ≥ 30 kg/m2 (obesity).
• • Adults with a BMI ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus.
• Helps reduce elevated blood glucose levels and HbA1c in adults with type 2 diabetes.
• May support reduction in body weight and waist circumference when used as directed with lifestyle modification.

Active Ingredients / Key Components:

• Tirzepatide – 7.5 mg per pre-filled pen (7.5 mg/0.5 ml solution for injection).
• Each pen delivers 0.5 ml of solution containing 7.5 mg tirzepatide for subcutaneous use.
• Excipients: Full excipient list is not available in the provided information. Please refer to the official package leaflet for complete excipient details.

Dosage & Administration / How to Use:

• Mounjaro is for subcutaneous injection only. Do not administer intravenously or intramuscularly.
• Starting dose: 2.5 mg tirzepatide once weekly for 4 weeks (using the appropriate strength pen as prescribed by your doctor).
• Dose escalation: After 4 weeks at 2.5 mg, the dose is increased to 5 mg once weekly. If additional glycaemic or weight control is needed, the dose may be increased in 2.5 mg increments (e.g. 7.5 mg, 10 mg, 12.5 mg, 15 mg) after a minimum of 4 weeks on the current dose, as directed by the physician.
• Maintenance doses: Common maintenance doses are 5 mg, 10 mg, or 15 mg once weekly. The 7.5 mg pen is typically used as an intermediate step in titration or as a maintenance dose if prescribed.
• Maximum dose: 15 mg once weekly.
• Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of lipodystrophy or skin irritation.
• Can be administered at any time of the day, with or without food, on the same day each week.
• If you are also using insulin, inject Mounjaro and insulin at different injection sites and never mix them in the same syringe.
• If a dose is missed and it is within 4 days (96 hours) of the missed dose, administer it as soon as possible. If more than 4 days have passed, skip the missed dose and take the next dose on the regularly scheduled day. Do not take two doses within 3 days of each other.
• Use exactly as prescribed by your doctor. Do not change your dose or stop treatment without consulting your healthcare provider.

Clinical Benefits:

• Improves glycaemic control in adults with type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.
• Promotes clinically significant weight loss and supports long-term weight management when combined with a reduced-calorie diet and increased physical activity.
• Helps lower HbA1c and fasting/postprandial blood glucose, reducing the risk of diabetes-related complications when used as part of a comprehensive treatment plan.
• Once-weekly dosing improves treatment convenience and may enhance adherence compared to daily injectable therapies.
• Dual GIP and GLP-1 receptor agonist activity may offer additional metabolic benefits beyond traditional GLP-1 receptor agonists, as demonstrated in clinical studies.

Warnings & Contraindications:

• Mounjaro (tirzepatide) is a prescription medicine and must only be used under the supervision of a qualified healthcare professional.
• Contraindicated in patients with known hypersensitivity to tirzepatide or any of the excipients.
• Not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Not a substitute for insulin in insulin-dependent patients.
• Use with caution in patients with a history of pancreatitis; if pancreatitis is suspected (e.g. severe abdominal pain, persistent vomiting), discontinue and seek immediate medical attention.
• May cause gastrointestinal adverse reactions (nausea, vomiting, diarrhoea); dehydration can occur, especially in patients with renal impairment. Maintain adequate fluid intake.
• Use with caution in patients with severe gastrointestinal disease, including severe gastroparesis, as experience is limited.
• Hypoglycaemia risk increases when used with insulin or sulfonylureas; dose adjustment of concomitant therapies may be required.
• Thyroid C-cell tumours have been observed in rodents with GLP-1 receptor agonists; the relevance to humans is unknown. Patients should report symptoms such as a neck mass, dysphagia, dyspnoea, or persistent hoarseness.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Safety in pregnancy and lactation has not been well established; treatment decisions must be individualized by the physician.
• Inform your doctor about all other medicines you are taking, including oral medications, as delayed gastric emptying may affect absorption of some drugs.
• Not intended for use in children and adolescents unless specifically prescribed by a specialist (pediatric data are limited).
• Do not share your pen with anyone else, even if the needle has been changed, to prevent cross-infection.
• Keep out of reach of children.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhoea, decreased appetite, constipation, indigestion, abdominal pain, and fatigue. These are often mild to moderate and may decrease over time as the body adjusts to treatment.
• Less common side effects: Injection site reactions (redness, itching, swelling), headache, dizziness, belching, gastroesophageal reflux, and mild dehydration.
• Serious side effects (seek immediate medical attention): Signs of pancreatitis (severe, persistent abdominal pain that may radiate to the back, with or without vomiting), signs of severe allergic reaction (rash, itching, swelling of face/lips/tongue/throat, difficulty breathing), signs of severe hypoglycaemia (confusion, seizures, loss of consciousness), or symptoms suggestive of gallbladder disease (severe abdominal pain, jaundice).
• If any side effect is severe, persistent, or concerning, stop using the product and contact your doctor or pharmacist promptly.

Storage Instructions:

Store Mounjaro pens in a refrigerator at 2–8 °c. Do not freeze. Protect from light by keeping the pen in its original carton until use. If necessary, and according to the official product leaflet, a pen may be kept at room temperature for a limited period (refer to the package insert for exact duration); do not expose to excessive heat. Do not use if the solution is cloudy, discoloured, or contains particles. Keep container tightly closed and out of reach of children.

Specifications:

• Product type: Prescription injectable diabetes and weight management medicine.
• Active ingredient: Tirzepatide 7.5 mg per 0.5 ml solution for injection.
• Strength: 7.5 mg/0.5 ml per pen.
• Route of administration: Subcutaneous injection (abdomen, thigh, or upper arm).
• Dosage form: Pre-filled pen for once-weekly use.
• Pack size: The note references “4 s.c. vial”; exact number of pens per pack for this presentation is not clearly specified in the provided data. Please refer to the marketed pack in Egypt for confirmation.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.